- Home
- ASC vs KALV Comparison
ASC vs KALV Comparison
Compare ASC & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASC
- KALV
- Stock Information
- Founded
- ASC 2010
- KALV N/A
- Country
- ASC Bermuda
- KALV United States
- Employees
- ASC N/A
- KALV N/A
- Industry
- ASC Marine Transportation
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- ASC Consumer Discretionary
- KALV Health Care
- Exchange
- ASC Nasdaq
- KALV Nasdaq
- Market Cap
- ASC 617.6M
- KALV 523.1M
- IPO Year
- ASC 2013
- KALV N/A
- Fundamental
- Price
- ASC $11.77
- KALV $9.49
- Analyst Decision
- ASC Buy
- KALV Strong Buy
- Analyst Count
- ASC 3
- KALV 4
- Target Price
- ASC $20.00
- KALV $29.00
- AVG Volume (30 Days)
- ASC 897.0K
- KALV 338.6K
- Earning Date
- ASC 11-06-2024
- KALV 12-05-2024
- Dividend Yield
- ASC 12.91%
- KALV N/A
- EPS Growth
- ASC 6.23
- KALV N/A
- EPS
- ASC 3.55
- KALV N/A
- Revenue
- ASC $422,624,000.00
- KALV N/A
- Revenue This Year
- ASC N/A
- KALV N/A
- Revenue Next Year
- ASC N/A
- KALV $179.39
- P/E Ratio
- ASC $3.31
- KALV N/A
- Revenue Growth
- ASC N/A
- KALV N/A
- 52 Week Low
- ASC $11.59
- KALV $7.39
- 52 Week High
- ASC $23.44
- KALV $16.88
- Technical
- Relative Strength Index (RSI)
- ASC 10.41
- KALV 33.65
- Support Level
- ASC $11.85
- KALV $10.78
- Resistance Level
- ASC $12.23
- KALV $11.62
- Average True Range (ATR)
- ASC 0.46
- KALV 0.79
- MACD
- ASC -0.10
- KALV -0.20
- Stochastic Oscillator
- ASC 6.21
- KALV 4.27
About ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.